Literatur
- 1
Barst R J, Rubin L J, McGoon M D, Caldwell E J, Long W A, Levy P S.
Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin.
Ann Intern Med.
1994;
121
409-415
- 2
Barst R J, Rubin L J, Long W A, McGoon M D, Rich S, Badesch D B, Groves B M, Tapson V F,
Bourge R C, Brundage B H, Koerner S K, Langleben D, Keller C A, Murali S, Uretsky B F,
Clayton L M, Jöbsis M M, Blackburn S D, Shortino D, Crow J W.
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional
therapy for primary pulmonary hypertension.
N Engl J Med.
1996;
334
296-301
- 3
Channick R N, Newhart J W, Johnson F W, Williams P J, Auger W R, Fedullo P F, Moser K M.
Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension:
an ambulatory delivery system and initial clinical tests.
Chest.
1996;
109
1545-1549
- 4
Conte J V, Gaine S P, Orens J B, Harris T, Rubin L J.
The influence of continous prostacyclin therapy for primary pulmonary hypertension
on the timing and outcome of transplantation.
J Heart Lung Transpl.
1998;
17
679-685
- 5
De Jaegere A PMC, van den Anker J N.
Endotracheal instillation of prostacyclin in preterm infants with persistant pulmonary
hypertension.
Eur Respir J.
1998;
12
932-934
- 6
Eichelbronner O, Reinelt H, Wiedeck H, Mezody M, Roissant R, Georgieff M. et al .
Aerosolized prostacyclin and inhaled nitric oxide in septic shock - different effects
on splanchnic oxygenation?.
Intensive Care Med.
1996;
22
880-887
- 7
Higenbottam T W, Butt A Y, DinhXuan A T, Takao M, Cremona G, Akamine S.
Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin
analogue, iloprost.
Heart.
1998;
79
175-179
- 8
Higenbottam T, Butt A Y, McMahon A, Westerbeck R, Sharples L.
Long term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe
pulmonary hypertension.
Heart.
1998;
80
151-155
- 9
McLaughlin V V, Genthner D E, Panella M M, Rich S.
Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin)
therapy in primary pulmonary hypertension.
N Engl J Med.
1998;
338
273-277
- 10
Okano Y, Yoshioka T, Shimouchi A, Satoh T, Kunieda T.
Orally active prostacyclin analogue in primary pulmonary hypertension.
Lancet.
1997;
349
1365
- 11
Olschewski H, Walmrath D, Schermuly R, Ghofrani H A, Grimminger F, Seeger W.
Aerosolized prostacyclin and iloprost in severe pulmonary hypertension.
Ann Intern Med.
1996;
124
820-824
- 12
Olschewski H, Ghofrani H A, Walmrath D, Temmesfeld-Wollbrück B, Grimminger F, Seeger W.
Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with
aerosolization of iloprost.
Intensive Care Med.
1998;
24
631-634
- 13
Olschewski H, Ghofrani H A, Walmrath D, Schermuly R, Temmesfeld-Wollbrück B, Grimminger F,
Seeger W.
Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung
fibrosis.
Am J Respir Crit Care Med.
1999;
160 (2)
600-607
- 14
Olschewski H, Ghofrani H A, Winkler J, Wilkens H, Höper M M, Behr J, Kleber F-X, Seeger W.
and the German PPH Study Group .
Inhaled iloprost to treat severe pulmonary hypertension: An uncontrolled trial.
Ann Intern Med.
2000;
132
435-443
- 15
Putensen C, Hormann C, Kleinsasser A, Putensen-Himmer G.
Cardiopulmonary effects of aerosolized prostaglandin E1 and nitric oxide inhalation
in patients with acute respiratory distress syndrome.
Am J Respir Care Med.
1998;
157
1743-1747
- 16
Rich S, Kaufmann E, Levy P S.
The effect of high doses of calcium channel blockers on survival in primary pulmonary
hypertension.
N Engl J Med.
1992;
327
76-81
- 17
Robbins I, Christman B W, Newman J H, Matlock R, Loyd J E.
A survey of diagnostic practices and the use of epoprostenol in patients with primary
pulmonary hypertension.
Chest.
1998;
114
1269-1275
- 18
Saji T, Ozawa Y, Ishikita T, Matsuura H, Matsuo N.
Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and
secondary pulmonary hypertension.
Am J Cardiol.
1996;
78
244-247
- 19
Sitbon O, Humbert M, Jagot J L, Taravella O, Fartoukh M, Parent F, Herve P, Simonneau G.
Inhaled nitric oxide as a screening agent for safely identifying responders to oral
calcium-channel blockers in primary pulmonary hypertension.
Eur Resp J.
1998;
12
265-270
- 20
Walmrath D, Schneider T, Pilch J, Grimminger F, Seeger W.
Aerosolized prostacyclin in adult respiratory distress syndrom.
Lancet.
1993;
342
961-962
- 21
Walmrath D, Schneider T, Pilch J, Schermuly R, Grimminger F, Seeger W.
Effects of aerosolized prostacyclin in severe pneumonia. Impact of fibrosis.
Am J Respir Crit Care Med.
1995;
151
724-730
- 22
Walmrath D, Schneider T, Schermuly R, Olschewski H, Grimminger F, Seeger W.
Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory
distress syndrome.
Am J Respir Crit Care Med.
1996;
153
991-996
- 23
Watkins W D, Peterson M B, Crone R K, Sharman D C, Levine L.
Prostacyclin and Prostaglandin E1 for severe idiopathic pulmonary hypertension.
N Engl J Med.
1980;
306
1326-1331
- 24
Zwissler B, Kemming G, Habler O, Kleen M, Merkel M, Haller M. et al .
Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratoy distress
syndrome.
Am J Respir Crit Care Med.
1996;
154
1671-1677
Dr H Olschewski
Ambulanz für Pulmonale Hypertonie Medizinische Klinik II Justus-Liebig-Universität
35392 Gießen
